CREB3L2 and neoplasm: Consistent with expectations, within the tumor xenograft model of 97H cells subjected to shCREB3L2 treatment, it was observed that the knockdown of CREB3L2 substantially inhibited tumor growth and reinstated the anti-tumor effectiveness of lenvatinib (Fig. 7F, G).